Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Phase 1

Completed

Conditions: Japanese Healthy Adult Male Participants

Interventions: Drug: TAK-906
Drug: TAK-906 Placebo

First Posted Date: 2017-08-02

Last Posted Date: 2021-01-12

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03237156

Locations: 🇯🇵
Sekino Clinical Pharmacology Clinic, Toshima, Tokyo, Japan

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab IV
Drug: Placebo

First Posted Date: 2017-07-31

Last Posted Date: 2023-03-01

Lead Sponsor: Takeda

Target Recruit Count: 215

Registration Number: NCT03234907

Locations: 🇨🇳
Gastroenterology, Hangzhou, Zhejiang, China

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin
Drug: Alogliptin

First Posted Date: 2017-07-27

Last Posted Date: 2023-12-22

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT03231709

Locations: 🇯🇵
OCROM Clinic, Suita, Osaka, Japan
🇯🇵
ToCROM Clinic, Shinjuku, Tokyo, Japan

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-418
Drug: TAK-418 Placebo

First Posted Date: 2017-07-24

Last Posted Date: 2019-09-09

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT03228433

Locations: 🇺🇸
PAREXEL International, Glendale, California, United States

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Phase 3

Recruiting

Conditions: Moderately to Severely Active Ulcerative Colitis

Interventions: Drug: Vedolizumab IV
Drug: Placebo

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 402

Registration Number: NCT03221036

Locations: 🇨🇳
Gastroenterology, Hangzhou, Zhejiang, China

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Completed

Conditions: Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Interventions: Drug: Vonoprazan
Drug: Amoxicillin hydrate
Drug: Clarithromycin
Drug: Metronidazole

First Posted Date: 2017-07-17

Last Posted Date: 2019-03-22

Lead Sponsor: Takeda

Target Recruit Count: 560

Registration Number: NCT03219723

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Completed

Conditions: Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Interventions: Drug: Vonoprazan

First Posted Date: 2017-07-12

Last Posted Date: 2019-12-12

Lead Sponsor: Takeda

Target Recruit Count: 3183

Registration Number: NCT03214952

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp alfa
Drug: Dexamethasone

First Posted Date: 2017-07-12

Last Posted Date: 2024-12-24

Lead Sponsor: Takeda

Target Recruit Count: 272

Registration Number: NCT03215030

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 91 locations

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: Vonoprazan

First Posted Date: 2017-07-11

Last Posted Date: 2019-10-23

Lead Sponsor: Takeda

Target Recruit Count: 1237

Registration Number: NCT03214081

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"

Completed

Conditions: A History of Gastric or Duodenal Ulcers

Interventions: Drug: Vonoprazan

First Posted Date: 2017-07-11

Last Posted Date: 2023-06-07

Lead Sponsor: Takeda

Target Recruit Count: 1304

Registration Number: NCT03214198

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy